News
Company News: Curetis Publishes Full-Year 2018 Financial Results and Updated Guidance for 2019
– Launched Unyvero System and Unyvero LRT Cartridge in the U.S.
– Increased revenues to EUR 1.4 million in 2018
– Raised EUR 19.5 million additional funding
– Revised focus and strategy
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the financial results for the twelve months ended December 31, 2018, and provided an updated guidance for 2019. Read more…
Company News: Curetis to Publish its Full-Year 2018 Financial Results on April 11, 2019
— Company to host earnings conference call on same day
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that it will publish its full-year 2018 financial results on April 11, 2019. In addition, the Company will host a public earnings conference call and webcast on April 11, 2019, at 03:00 pm CET / 09:00 am EDT to present the financial results of 2018, highlight the most important events in 2018 and provide an outlook for 2019. Read more…
Company News: Curetis – Study Data Presented at ECCMID 2019 Confirm Clinical Benefits of Unyvero Platform
— Growing body of evidence shows benefits of Unyvero for antibiotic stewardship
— 8 new reports on European studies presented by clinical researchers using Unyvero HPN, ITI, BCU and IAI
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that novel products, data, and services will be presented during this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, The Netherlands, from April 13 – 16, 2019. Curetis can be found at booth 1.65 during the conference. Read more…
Company News: Curetis Introduces Unyvero AMR Atlas to Support Adoption of Rapid DNA Testing for Antibiotic Resistance
— Knowledge base of antimicrobial resistance (AMR) markers tailored specifically to Unyvero Applications
— Developed by Curetis’ subsidiary Ares Genetics and powered by ARESdb
— Initial focus on Unyvero Pneumonia Applications
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that it will introduce its newly developed Unyvero AMR Atlas at the upcoming 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will take place in Amsterdam, the Netherlands, on April 13-16, 2019. Read more…